Bates A S, Evans A J, Jones P, Clayton R N
Department of Postgraduate Medicine, University of Keele, Stoke-on-Trent, UK.
Clin Endocrinol (Oxf). 1995 Apr;42(4):425-30. doi: 10.1111/j.1365-2265.1995.tb02652.x.
The benefits of treating adults with GH deficiency are now well recognized although the criteria for deciding which patients to treat are still not clear. At present the 'gold standard' is the insulin stress test (IST) which is unpleasant and potentially dangerous, particularly in patients with hypopituitarism. The aim of this study was to determine whether alternative methods of assessing GH status are reliable in predicting GH deficiency.
Forty-four patients with unequivocal GH deficiency (peak IST < 2 mU/l) and 17 with partial deficiency (peak IST 2-10 mU/l) were studied. Each patient was assessed clinically with respect to the number of other pituitary axes affected and biochemically with an estimate of urinary GH excretion (uGH) and serum IGF-I. These markers were then related to GH status as defined by insulin stress testing.
Insulin stress tests were performed using 0.1 units/kg i.v. and accepted with a blood glucose < 2 mmol/l. Serum GH and IGF-I were measured by radioimmunoassay whilst uGH was estimated by an immunoradiometric assay using commercially available reagents. uGH was estimated from the mean of two overnight urine collections which consisted of all urine passed from last voiding through to the first morning sample.
The presence of unequivocal GH deficiency (peak IST < 2 mU/l) was predictable if 2 or more other pituitary axes were affected (90%). uGH declined significantly with the level of peak IST response (P < 0.001) and almost so with the number of other deficient hypothalamic-pituitary axes affected (P = 0.057). Thus, uGH accurately reflected GH status and showed good separation from normal controls in patients less than 40 years (specificity 79%) and between 40 and 60 years (specificity 67%). Above this age the method is less specific (36%). Patients excreted significantly less GH than controls in all three age groups (P < 0.01). Subnormal levels of IGF-I were strongly predictive of unequivocal GH deficiency (91% with subnormal IGF-I have a peak IST GH < 2 mU/l) although a normal value does not reliably exclude the diagnosis.
A diagnosis of adult GH deficiency can be reliably made without the need for an insulin stress test by using a combination of low urinary GH excretion, subnormal IGF-I levels and clinical assessment with regard to the number of other pituitary axes affected.
虽然生长激素(GH)缺乏症成人患者的治疗益处已得到广泛认可,但决定哪些患者需要治疗的标准仍不明确。目前,“金标准”是胰岛素耐量试验(IST),该试验令人不适且存在潜在风险,尤其对于垂体功能减退患者。本研究旨在确定评估GH状态的替代方法在预测GH缺乏方面是否可靠。
对44例明确诊断为GH缺乏(IST峰值<2 mU/l)和17例部分缺乏(IST峰值2 - 10 mU/l)的患者进行研究。对每位患者进行临床评估,了解受影响的其他垂体轴数量,并进行生化评估,包括估算尿GH排泄量(uGH)和血清胰岛素样生长因子I(IGF-I)。然后将这些指标与胰岛素耐量试验定义的GH状态相关联。
采用静脉注射0.1单位/千克胰岛素进行胰岛素耐量试验,当血糖<2 mmol/l时试验结果有效。采用放射免疫分析法测定血清GH和IGF-I,使用市售试剂通过免疫放射分析法定量uGH。uGH通过两次夜间尿液收集的平均值估算,尿液收集包括从上次排尿到次日晨尿的所有尿液。
如果有2个或更多其他垂体轴受影响,则可预测明确的GH缺乏(IST峰值<2 mU/l)(90%)。uGH随IST峰值反应水平显著下降(P<0.001),与受影响的其他下丘脑 - 垂体轴缺乏数量下降趋势相近(P = 0.057)。因此,uGH准确反映了GH状态,并且在年龄小于40岁的患者(特异性79%)和40至60岁的患者(特异性67%)中与正常对照有良好区分。超过这个年龄,该方法特异性较低(36%)。在所有三个年龄组中,患者的GH排泄量均显著低于对照组(P<0.01)。IGF-I水平低于正常强烈预测明确的GH缺乏(IGF-I低于正常的患者中91%的IST峰值GH<2 mU/l),尽管正常数值并不能可靠地排除诊断。
通过结合低尿GH排泄量、低于正常的IGF-I水平以及对其他受影响垂体轴数量的临床评估,无需进行胰岛素耐量试验即可可靠地诊断成人GH缺乏症。